Dr. Andrea Apolo

So I'm excited about the antibody drug conjugates in combination with checkpoint inhibitor trials. There's three large trials, and this is, of course, because of the amazing 302 data where we saw doubling of the overall survival in patients in the first-line treatment with metastatic bladder cancer.

And there are several trials that are ongoing right now asking that question in the perioperative setting. And similar to what we saw with the cisplatinum plus checkpoint inhibitor trials, they have a neoadjuvant component and an adjuvant component.

And there are several trials that are ongoing right now asking that question in the perioperative setting. And similar to what we saw with the cisplatinum plus checkpoint inhibitor trials, they have a neoadjuvant component and an adjuvant component.

And there are several trials that are ongoing right now asking that question in the perioperative setting. And similar to what we saw with the cisplatinum plus checkpoint inhibitor trials, they have a neoadjuvant component and an adjuvant component.

So there's the EV304 study for patients that are cisplatinum eligible where they get EV plus PEMBRO and in the neoadjuvant setting, and then they get it in the adjuvant setting, and then there's the control arm study. that just get neoadjuvant cisplatinum-based chemotherapy and nothing in the adjuvant setting. And then we saw a little bit of data from the Volga study at ESMO.

So there's the EV304 study for patients that are cisplatinum eligible where they get EV plus PEMBRO and in the neoadjuvant setting, and then they get it in the adjuvant setting, and then there's the control arm study. that just get neoadjuvant cisplatinum-based chemotherapy and nothing in the adjuvant setting. And then we saw a little bit of data from the Volga study at ESMO.

So there's the EV304 study for patients that are cisplatinum eligible where they get EV plus PEMBRO and in the neoadjuvant setting, and then they get it in the adjuvant setting, and then there's the control arm study. that just get neoadjuvant cisplatinum-based chemotherapy and nothing in the adjuvant setting. And then we saw a little bit of data from the Volga study at ESMO.

And this was basically the safety run-in with the triplet EV, DERVA, TREMI in the neoadjuvant setting and then in the adjuvant setting. And they were really looking at clearance of ctDNA. And they found that There's a pathologic complete response rate, and there's also downstaging of the tumor, and there's clearance of the ctDNA. So that may be a good biomarker for efficacy. So more to come.

And this was basically the safety run-in with the triplet EV, DERVA, TREMI in the neoadjuvant setting and then in the adjuvant setting. And they were really looking at clearance of ctDNA. And they found that There's a pathologic complete response rate, and there's also downstaging of the tumor, and there's clearance of the ctDNA. So that may be a good biomarker for efficacy. So more to come.

And this was basically the safety run-in with the triplet EV, DERVA, TREMI in the neoadjuvant setting and then in the adjuvant setting. And they were really looking at clearance of ctDNA. And they found that There's a pathologic complete response rate, and there's also downstaging of the tumor, and there's clearance of the ctDNA. So that may be a good biomarker for efficacy. So more to come.

It was really small. It was like 17 patients in the lead-in. But I think exciting in that, you know, the trial is... going forward. And there's multiple arms to that study. So they only showed the safety of the triplet. There's also a doublet with EV plus Dervalumab and then Dervalumab as adjuvant. And then the weird part is that the control arm is no therapy.

It was really small. It was like 17 patients in the lead-in. But I think exciting in that, you know, the trial is... going forward. And there's multiple arms to that study. So they only showed the safety of the triplet. There's also a doublet with EV plus Dervalumab and then Dervalumab as adjuvant. And then the weird part is that the control arm is no therapy.

It was really small. It was like 17 patients in the lead-in. But I think exciting in that, you know, the trial is... going forward. And there's multiple arms to that study. So they only showed the safety of the triplet. There's also a doublet with EV plus Dervalumab and then Dervalumab as adjuvant. And then the weird part is that the control arm is no therapy.

But in all fairness, that's kind of what we did with our patients if they were not cisplatinum eligible. We didn't give them cisplatinum-based therapy because they can't receive it. We don't give them carboplatinum. And then we observed them in the adjuvant setting. So that's the control arm for the Volga study.

But in all fairness, that's kind of what we did with our patients if they were not cisplatinum eligible. We didn't give them cisplatinum-based therapy because they can't receive it. We don't give them carboplatinum. And then we observed them in the adjuvant setting. So that's the control arm for the Volga study.

But in all fairness, that's kind of what we did with our patients if they were not cisplatinum eligible. We didn't give them cisplatinum-based therapy because they can't receive it. We don't give them carboplatinum. And then we observed them in the adjuvant setting. So that's the control arm for the Volga study.

And then there's another trial also for patients that are cisplatinum ineligible, the EV303 study. And that one is EV plus PEMBRO again in the neoadjuvant setting and then in the adjuvant setting. And this is the great thing about EV plus PEMBRO is that it doesn't matter whether you are cisplatinum eligible or not. You can get this treatment. So they're, again, sandwiching it.

And then there's another trial also for patients that are cisplatinum ineligible, the EV303 study. And that one is EV plus PEMBRO again in the neoadjuvant setting and then in the adjuvant setting. And this is the great thing about EV plus PEMBRO is that it doesn't matter whether you are cisplatinum eligible or not. You can get this treatment. So they're, again, sandwiching it.

And then there's another trial also for patients that are cisplatinum ineligible, the EV303 study. And that one is EV plus PEMBRO again in the neoadjuvant setting and then in the adjuvant setting. And this is the great thing about EV plus PEMBRO is that it doesn't matter whether you are cisplatinum eligible or not. You can get this treatment. So they're, again, sandwiching it.

And they also have a monotherapy PEMBRO arm. And then they have a no therapy arm where they get no therapy in the neoadjuvant and no therapy in the adjuvant setting. So I'm excited about these trials.